Radium-223 for the treatment of bone metastasis of prostate cancer.
- Author:
Xiao-Feng XU
1
;
Zhi-Feng WEI
1
;
Zheng-Yu ZHANG
1
Author Information
1. Department of Urology, Nanjing General Hospital of Nanjing Military Region, Nanjing, Jiangsu 210002, China.
- Publication Type:Journal Article
- Keywords:
bone metastasis;
prostate cancer;
radium-223;
treatment
- MeSH:
Bone Neoplasms;
radiotherapy;
secondary;
Clinical Trials as Topic;
Humans;
Male;
Prostatic Neoplasms;
pathology;
Quality of Life;
Radioisotopes;
Radium;
therapeutic use
- From:
National Journal of Andrology
2017;23(1):78-81
- CountryChina
- Language:Chinese
-
Abstract:
Over 80% of the patients with prostate cancer (PCa) develop bone metastasis, which seriously affects the patients' quality of life and remains a major cause of morbidity. Radium-223 (Ra-223), a newly approved agent targeting bone metastasis of PCa, can improve the quality of life and prolong the overall survival of the PCa patients with bone metastasis. This article presents an overview of the clinical trials recently published on the management of bone metastasis of PCa with Ra-223.
